Flash Finance

Vilin Bio Med LimitedVILINBIOCorporate

Pharmaceuticals - Indian - Bulk Drugs Latest results: Mar 2026 9 quarters of data
₹54.65
MCap ₹83 Cr · P/E 43.2
Vilin Bio Med Limited — Stock analysis & AI research Vilin Bio Med Limited — Multibagger AI analysis Vilin Bio Med Limited — Seasonality — best & worst months Vilin Bio Med Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹33 Cr
Sales · Mar 2026
+215.9% YoY
₹3 Cr
Operating Profit · Mar 2026
+673.0% YoY
8.8%
OPM % · Mar 2026
+144.4% YoY
₹2 Cr
Net Profit · Mar 2026
+1680.0% YoY
₹1.17
EPS · Mar 2026
+1571.4% YoY

📝 Vilin Bio Med Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Vilin Bio Med Limited reported revenue of ₹33 crore for the quarter ended March 2026 (Q4 FY26), up 215.9% from ₹10 crore in the same quarter last year.

Net profit rose 1680.0% year-on-year to ₹2 crore, from ₹0 crore. Earnings per share (EPS) came in at ₹1.17.

Operating profit stood at ₹3 crore — an operating margin (OPM) of 8.8%, compared with 3.6% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹42 crore with a net profit of ₹2 crore.

Valuation snapshot

At the current price of ₹54.65, VILINBIO has a market capitalisation of ₹83 crore and a trailing P/E of about 43.2.

Within the Pharmaceuticals - Indian - Bulk Drugs industry, it is the 11th-largest of the 11 companies we track by market value.

Shareholding pattern

As of May 2026, promoters held 56.65%, public shareholders 43.35% of Vilin Bio Med Limited.

Promoter holding slipped from 59.57% to 56.65% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹83 Cr
Current Price ?
₹54.6
P/E ?
43.18above ind
Industry P/E ?
32.10
P/B ?
2.94
P/S ?
1.97
P/FCF ?
208.35
Enterprise Value ?
₹84 Cr
EV/EBITDA ?
26.11
PEG ?
2.70
Earnings Yield ?
3.5%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹42 Cr
OPM ?
7.6%
Profit after tax (TTM) ?
₹2 Cr
EPS (TTM) ?
₹1.27
ROCE ?
10.8%
ROE ?
6.8%
ROA ?
5.5%
Growth
Sales — latest qtr ?
₹33 Cr
PAT — latest qtr ?
₹2 Cr
YoY qtr sales growth ?
215.9%
YoY qtr profit growth ?
1,680.0%
Sales growth (3y) ?
51%
Sales growth (5y) ?
30%
Profit growth (3y) ?
16%
Profit growth (5y) ?
74%
Financial Health
Debt ?
₹0 Cr
Debt to Equity ?
0.01
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
56.65%
Change in promoter holding ?
-7.24%
Pledged percentage ?
N/A
Market
Return 3 months ?
29.3%
Return 6 months ?
46.5%

🗓️ Quarterly results (9 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026 YoY % QoQ %
Sales 548884101033 +215.9% —
Operating Profit 0111-10003 +673.0% —
Other Income 000000000 -100.0% —
Interest 000000000 -100.0% —
Depreciation 000000000 +600.0% —
Profit Before Tax 0111-10003 +1666.7% —
Net Profit 0111-10002 +1680.0% —
EPS 0.061.670.690.55-0.440.090.070.111.17 +1571.4% —
OPM % 7.9% 27.1% 17.9% 18.2% -7.0% 9.4% 3.6% 3.5% 8.8% +144.4% —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 9.9513.9513.9515.25 +9.3%
Reserves 0.738.899.1113.12 +44.0%
Borrowings 4.936.832.570.21 -91.8%
Other Liabilities 2.072.732.106.36 +202.9%
Total Liabilities 17.6832.4027.7334.94 +26.0%
Fixed Assets 1.511.381.282.87 +124.2%
CWIP 0.000.001.570.00 -100.0%
Investments 0.000.000.000.00 —
Other Assets 16.1731.0224.8832.07 +28.9%
Total Assets 17.6832.4027.7334.94 +26.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -1.66-7.420.220.70 +218.2%
Cash from Investing Activity -0.030.32-1.11-0.30 +73.0%
Cash from Financing Activity 1.688.87-5.101.01 +119.8%
Net Cash Flow 0.001.77-5.991.41 +123.5%
Free Cash Flow -1.69-7.42-1.350.40 +129.6%
CFO/OP -43%-888%37%49% +32.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 166.04131.22155.51137.85 -11.4%
Inventory Days 44.74125.41119.5070.03 -41.4%
Days Payable 60.4954.7137.6732.49 -13.8%
Cash Conversion Cycle 150.28201.91237.35175.38 -26.1%
Working Capital Days 45.0776.23195.44168.16 -14.0%
ROCE % 17.17%4.51%4.20%10.77% +156.4%

👥 Shareholding (latest 4 periods)

Metric Sep 2025Dec 2025Mar 2026May 2026 % Chg
Promoters 63.89%63.65%59.57%56.65% -4.9%
Public 36.11%36.35%40.43%43.35% +7.2%
No. of Shareholders 476462397400 +0.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs · 11 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SMSPHARMA SMS Pharmaceuticals ₹442.45 4,144 39.7 898 102 19.3% 11.4% 13.3% 48.6% 5.6% -1.4%
2 AARTIDRUGS Aarti Drugs ₹428.30 3,909 20.5 2,678 191 12.4% 7.1% 7.5% 16.3% 18.9% -7.2%
3 HIKAL Hikal ₹229.83 2,834 — 1,734 -34 13.4% -2.0% -8.0% -154.4% 6.0% 67.0%
4 BETA Beta Drugs ₹2,064.90 2,084 37.5 513 57 20.5% 11.2% — — 25.5% 31.7%
5 NGLFINE NGL Fine-Chem ₹2,786.60 1,722 30.1 536 57 15.6% 10.6% 36.0% 123.2% 33.6% 99.1%
6 ANUHPHR Anuh Pharma ₹92.99 932 21.1 779 44 8.6% 5.7% 16.5% -12.8% 4.2% 42.8%
7 INFINIUM Infinium Pharma ₹222.95 347 31.2 190 14 11.3% 7.2% — — 45.2% 166.7%
8 AAREYDRUGS Aarey Drugs ₹98.71 329 67.1 415 4 1.6% 1.0% -0.4% 12.3% -56.3% -25.3%
9 PAR Par Drugs ₹128.90 159 10.9 109 14 18.3% 13.3% 2.7% -1.9% 20.1% 41.6%
10 KREBSBIO Krebs Biochemicals ₹57.94 125 — 25 -14 -10.0% -55.9% -45.2% 37.1% 27.4% 53.3%
11 VILINBIO Vilin Bio ₹18.00 27 14.2 42 2 7.6% 4.6% — — 215.9% 1680.0%
❓ Frequently asked questions
What was Vilin Bio Med Limited's revenue in Q4 FY26?
Vilin Bio Med Limited reported revenue of ₹33 crore for the quarter ended March 2026 (Q4 FY26), up 215.9% from ₹10 crore in the same quarter last year.
What was Vilin Bio Med Limited's net profit in Q4 FY26?
Net profit rose 1680.0% year-on-year to ₹2 crore, from ₹0 crore. Earnings per share (EPS) came in at ₹1.17.
What is VILINBIO's market capitalisation and P/E ratio?
At the current price of ₹54.65, VILINBIO has a market capitalisation of ₹83 crore and a trailing P/E of about 43.2.
Who owns Vilin Bio Med Limited? (shareholding pattern)
As of May 2026, promoters held 56.65%, public shareholders 43.35% of Vilin Bio Med Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI